All In Biotech

Drug Trial Radar · NCT06855277

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 940 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

940

Planned (sponsor's estimate)

Start

Jul 1, 2025

Primary completion

Sep 29, 2028

Study completion Nov 4, 2032

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of standard of care (SOC) (ARPI change or taxane-based chemotherapy or \[177Lu\]Lu-PSMA-617 (AAA617)) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) treated with another ARPI as last treatment and who have not been exposed to a taxane-containing chemotherapy in the mCRPC setting nor have received any prior PSMA-targeting radioligand therapy.

Conditions

  • Prostate Cancer

Interventions

  • AAA817Drug

    AAA817 is being studied for treating PSMA positive mCRPC. Inside the body, it attaches itself to PSMA on the cell surface of the prostate cancer cells and emits radiation to kill them. This treatment is also called a radioligand therapy.

  • ARPIDrug

    Androgen receptor pathway inhibitor (ARPI): An ARPI is approved for the treatment of prostate cancer. It works by blocking signals from male hormones, such as testosterone, that helps cancer cells grow. By blocking these signals, an ARPI slows down or stops the growth of prostate cancer cells. In this trial, participants will be given either enzalutamide or abiraterone.

  • Standard of CareDrug

    Standard treatment includes approved treatment for mCRPC. In this trial, the trial doctor will decide which available treatment participants will receive. The trial doctor will select either an ARPI of enzalutamide or abiraterone, or a taxane based chemotherapy of docetaxel or cabazitaxel or \[177Lu\]Lu-PSMA-617 (AAA617).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiographic Progression Free Survival (rPFS)Time frame: From the date of randomization to the date of the first documented radiographic disease progression using conventional imaging, or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.

Locations

106 sites in 12 countries. Site status is shown where the registry gives one.

  • Urology Centers Of Alabama Pc

    Homewood, Alabama · Recruiting

  • University of Arizona

    Tucson, Arizona · Recruiting

  • Univ Cali Irvine ALS Neuromuscular

    Orange, California · Recruiting

  • Stanford University Medical Center

    Palo Alto, California · Recruiting

  • Sansum Clinic

    Santa Barbara, California · Recruiting

  • Rocky Mountain Cancer Centers

    Denver, Colorado · Recruiting

  • Florida Cancer Specialists

    Fort Myers, Florida · Recruiting

  • Baptist Health South

    Miami, Florida · Recruiting

  • AdventHealth

    Orlando, Florida · Recruiting

  • University Cancer and Blood Center LLC

    Athens, Georgia · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • University of Illinois Cancer Center at Chicago

    Chicago, Illinois · Recruiting

  • Univ Of Iowa Hospitals And Clinics

    Iowa City, Iowa · Recruiting

  • University of Kansas Hospital

    Kansas City, Kansas · Recruiting

  • East Jefferson Hospital

    Metairie, Louisiana · Recruiting

  • New England Cancer Specialists

    Scarborough, Maine · Recruiting

  • Johns Hopkins Hospital

    Baltimore, Maryland · Recruiting

  • Beth Israel Deaconess Med Center

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Wash U School of Medicine

    St Louis, Missouri · Recruiting

  • Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • Astera Cancer Center

    East Brunswick, New Jersey · Recruiting

  • New Jersey Urology LLC

    Voorhees Township, New Jersey · Recruiting

  • New Mexico Oncology Hematology

    Albuquerque, New Mexico · Recruiting

  • Bassett Medical Center

    Cooperstown, New York · Recruiting

  • Weill Cornell Medicine NY-Presb

    New York, New York · Recruiting

  • University of Rochester Medical Ctr

    Rochester, New York · Recruiting

  • Associated Med Professionals of NY

    Syracuse, New York · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • Urology Group - Solaris Network

    Cincinnati, Ohio · Recruiting

  • Central Ohio Urology Group

    Gahanna, Ohio · Recruiting

  • MUSC Hollings Cancer Center

    Charleston, South Carolina · Recruiting

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina · Recruiting

  • Tennessee Oncology PLLC

    Chattanooga, Tennessee · Recruiting

  • Urology Austin

    Lakeway, Texas · Recruiting

  • Urology San Antonio

    San Antonio, Texas · Recruiting

  • Woodlands Cancer Institute American Oncology Partners

    The Woodlands, Texas · Recruiting

  • Swedish Medical Center

    Seattle, Washington · Recruiting

  • Northwest Medical Specialties

    Tacoma, Washington · Recruiting

Showing 40 of 106 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.